Literature DB >> 2400370

Threshold altitude resulting in decompression sickness.

K V Kumar1, J M Waligora, D S Calkins.   

Abstract

A review of case reports, hypobaric chamber training data, and experimental evidence indicated that the threshold for incidence of Altitude Decompression Sickness (DCS) was influenced by various factors such as prior denitrogenation, exercise or rest and period of exposure, in addition to individual susceptibility. Fitting these data with appropriate statistical models has the potential for estimating the frequency of occurrence of DCS at various altitudes under different experimental conditions and allows us to examine the influence of various factors on the threshold for DCS. This approach was illustrated by logistic regression analysis on the incidence of DCS below 9,144 m (30,000 ft). Estimations using these regressions showed that under a noprebreathe, 6-h exposure, simulated extravehicular activity profile, the threshold for symptoms occurred at approximately 3,353 m (11,000 ft); while under a no-prebreathe, 2-h exposure profile with knee-bends exercise, the threshold occurred at 7,925 m (26,000 ft). These examples showed that definition of threshold altitude should be qualified by the particular combination of experimental variables under which it was observed.

Mesh:

Year:  1990        PMID: 2400370

Source DB:  PubMed          Journal:  Aviat Space Environ Med        ISSN: 0095-6562


  3 in total

1.  High-altitude decompression illness: case report and discussion.

Authors:  G Michael Allan; David Kenny
Journal:  CMAJ       Date:  2003-10-14       Impact factor: 8.262

2.  Decompression Illness Treated with the Hart-Kindwall Protocol in a Monoplace Chamber.

Authors:  Yoshiaki Inuzuka; Naoki Edo; Yuichi Araki; Takafumi Hoshi; Mayuko Maruta; Nana Nakamoto; Shinya Suzuki
Journal:  Am J Case Rep       Date:  2022-06-12

3.  Investigation of a cluster of decompression sickness cases following a high-altitude chamber flight.

Authors:  Nazim Ata; Erkan Karaca
Journal:  Diving Hyperb Med       Date:  2021-03-31       Impact factor: 0.887

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.